Abbisko Therapeutics Co., Ltd

Novartis Ag

Haibing Deng

Hongping Yu

Yaochang Xu

Zhui Chen

Fei Yang

Chao Chen

Feng He

Lei Jiang

Yuan Mi

Ce Wang

Haibing Guo

Fang Liang

Guoliang Xun

Yao-Chang Xu

Haiyan Ying

Huixin Wan

Qitao Xiao

Counde Oyang

Jinbiao Liu

Haiqiang Zeng

Ji Yue Zhang

Ji Yue (Jeff) Zhang

A compound having a structure of formula (I) and a preparation method therefor, and a use of the compound serving as an FGFR inhibitor for treating tumors, cancers, myeloproliferative diseases, bone or chondrocyte disorders, and hypophosphatemia.

FGFR inhibitor, preparation method therefor and application thereof

The present invention provides a compound of Formula (I):

Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents

A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof are provided. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.

CD73 inhibitor, preparation method therefor and application thereof

Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs. 

FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof

The present invention provides a compound of Formula (I): 

Formylpyridine derivatives having FGFR4 inhibitory activities, a preparation method therefor and use thereof are described. In particular, the formylpyridine derivatives have a structure of formula (I), and the definition of each substituent in the formula are described in the description and claims. The series of compounds of the formula (I) have very strong inhibitory effects on FGFR4 kinases and very high selectivity, and can be widely used in the preparation of medicaments for treating cancers, particularly prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, stomach cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, neuroglioblastoma or rhabdomyosarcoma, and prospectively will be further developed to become a new generation of FGFR4 inhibitors. 

Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Triazolopyridine compounds

Growing community of inventors

Shanghai, China

Haibing Deng